This is the Scientific Surgery Archive, which contains all randomized clinical trials in surgery that have been identified by searching the top 50 English language medical journal issues since January 1998. Compiled by Jonothan J. Earnshaw, former Editor-in-Chief, BJS
Effect of low molecular weight heparin (dalteparin) and fondaparinux (Arixtra®) on human osteoblasts in vitro. BJS 2005; 92: 177-183.
Published: 6th December 2004
Authors: A. E. Handschin, O. A. Trentz, S. P. Hoerstrup, H. J. Kock, G. A. Wanner, O. Trentz et al.
Background
The prolonged administration of heparin for prevention and treatment of venous thromboembolism has been associated with a risk of heparin‐induced osteoporosis. Fondaparinux is a new antithrombotic drug that specifically inhibits factor Xa. Because of the known interactions of other antithrombotic agents with bone remodelling, the effects of fondaparinux on human osteoblasts were analysed in vitro.
Method
Primary human osteoblast cell cultures were incubated with either the low molecular weight heparin dalteparin at concentrations of 30, 300 and 900 µg/ml or with fondaparinux at concentrations of 25, 50, 100, 150, 200 and 250 µg/ml. Cellular proliferation rate and protein synthesis were measured. Expression of genes encoding osteocalcin, collagen type I and alkaline phosphatase was examined by reverse transcriptase–polymerase chain reaction.
Results
Incubation with dalteparin led to a significant, dose‐dependent inhibition of osteoblast proliferation, inhibition of protein synthesis, and inhibited expression of phenotype markers (osteocalcin and alkaline phosphatase genes) after 3 and 7 days. No inhibitory effects were observed in the fondaparinux‐treated cells.
Conclusion
Fondaparinux did not inhibit osteoblast proliferation in vitro and may reduce the risk of heparin‐induced osteoporosis associated with long‐term heparin administration. Copyright © 2004 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
Full text